SEOUL, March 23 (Korea Bizwire) — South Korean biopharmaceutical firm Celltrion Inc. said Monday that it is accelerating work on a treatment for the novel coronavirus as part of its efforts to address the global pandemic. The company was earlier selected as a preferred developer for a monoclonal antibody project to treat and prevent COVID-19 [...]
SEOUL, Jan. 21 (Korea Bizwire) — Major South Korean biosimilar manufacturer Celltrion Inc. said Tuesday it will spend 600 billion won (US$520 million) on its new plant in China over the next five years. The planned plant, with a production capacity of 120,000 liters of biopharmaceutical products, will be located in the central city of [...]
SEOUL, Jan. 16 (Korea Bizwire) — Major South Korean biosimilar manufacturer Celltrion Inc. plans to build a plant in China in a move to directly advance into the world’s second-largest biopharmaceutical market, its chief said. “We are in the final stage of signing a contract with the Chinese government. We will soon announce details of [...]
SEOUL, May 16 (Korea Bizwire) — Celltrion Inc. will invest 40 trillion won (US$33.7 billion) and create 110,000 jobs by 2030 as the South Korean biosimilar firm moves to take a leap forward as a global player, the company’s chairman said Thursday. The company’s business roadmap centers on cooperating with local governments to make the [...]
SEOUL, Apr. 27 (Korea Bizwire) — South Korea’s pharmaceutical giant Celltrion has become a strong competitor to European and U.S. drugs with its biosimilars, indicated by changes in sales, industry officials said Friday. Multinational drugmaker Roche logged a 44 percent fall in sales of Mabthera, an antibody used to treat rheumatoid arthritis, lymphoma and some [...]
SEOUL, March 28 (Korea Bizwire) — An affiliate of South Korean biopharmaceutical firm Celltrion Inc. said Wednesday that the market share of the biosimilar drug Remsima came to 52 percent in Europe during the fourth quarter of last year. The market share of Remsima surpassed that of its original drug, Remicade, by Janssen Biotech, Inc., [...]
SEOUL, March 23 (Korea Bizwire) – The head of South Korean biopharmaceutical firm Celltrion Inc. said Friday that the company is considering building a plant in Asia in a move to boost production capacity amid rising sales. “I will prioritize a country where Celltrion can have 100 percent stake in the plant to prevent technology [...]
SEOUL, Feb. 21 (Korea Bizwire) — South Korean biopharmaceutical firm Celltrion Inc.’s biosimilar drug Truxima will reach the Colombian market, the company’s affiliate said Wednesday. Global drug firm Mundi Pharma Inc. won exclusive rights to distribute and market the copy of Roche’s blockbuster medicine, also known as MabThera, in the South American country, Celltrion Healthcare [...]
SEOUL, Jan. 22 (Korea Bizwire) — The amount of stock sales through block deals on South Korean bourses increased sharply in 2017 from a year earlier, the Korea Exchange (KRX) said Monday. The amount surged to 55.9 trillion won (US$52.3 billion) on the KOSPI main bourse last year, up 37 percent from the previous year. [...]
SEOUL, Jan. 8 (Korea Bizwire) – Drugmaker Celltrion Inc.’s stock has made significant gains in recent days, surpassing Hyundai Motor Co. in terms of market value, data showed Monday. Celltrion shares jumped 55.12 percent over the past 7 trading sessions to 302,500 won (US$283.29) on Monday closing, pushing the company’s capitalization to a record 37.1 trillion won. Hyundai Motor’s market capitalization stood at 33.2 trillion won as of Monday closing. Celltrion’s [...]